Cancer researchers at Fox Chase Cancer Center in Philadelphia see promise in personalized medicine to help crack the code on ...

Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks ...

People inherit two copies of each gene—one from each parent—an evolutionary fail-safe to ensure survival even when one of ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) said long-term data from a Phase 3 study showed that 87.5% of patients treated with their breast cancer drug Lynparza were still alive six years later, ...

For instance, researchers are learning that the BRCA gene mutations most commonly associated with breast cancer also increase ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast ...

For cancer-suppressor genes like BRCA1, researchers have long hypothesized that a single healthy copy could still guard against tumor development. Yet women with one harmful BRCA1 mutation are far ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

据《美国医学会杂志》发表的研究披露，研究人员开展的一项分析包括了近1万名BRCA1 或 BRCA2基因变异的妇女，这项分析旨在估测有这些基因突变的 ...

Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer ...